Home>>Signaling Pathways>> GPCR/G protein>> LPL Receptor>>ONO-9780307

ONO-9780307 Sale

目录号 : GC63128

ONO-9780307 是一种特异性的 LPA1 (lysophosphatidic acid receptor 1) 拮抗剂,其IC50 的值为 2.7 nM。

ONO-9780307 Chemical Structure

Cas No.:856691-44-6

规格 价格 库存 购买数量
5 mg
¥8,640.00
现货
10 mg
¥13,950.00
现货

电话:400-920-5774 Email: sales@glpbio.cn

Customer Reviews

Based on customer reviews.

Sample solution is provided at 25 µL, 10mM.

产品文档

Quality Control & SDS

View current batch:

产品描述

ONO-9780307 is a specific synthetic LPA1 (lysophosphatidic acid receptor 1) antagonist with an IC50 value of 2.7 nM[1].

VT107 (0.1~10000 μM; LPA1-B103 and Vector-B103 cells) results in inhibition of Ca2+ mobilization[1].ONO-9780307 is used to solve the LPA1 crystal structure, binds to an orthosteric site in LPA1[1].

[1]. Mizuno H, et al. Lysophospholipid G protein-coupled receptor binding parameters as determined by backscattering interferometry. J Lipid Res. 2019;60(1):212-217.

Chemical Properties

Cas No. 856691-44-6 SDF
分子式 C30H35NO7 分子量 521.6
溶解度 DMSO : 190 mg/mL (364.26 mM; Need ultrasonic) 储存条件 4°C, protect from light
General tips 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。
为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。
Shipping Condition 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。

溶解性数据

制备储备液
1 mg 5 mg 10 mg
1 mM 1.9172 mL 9.5859 mL 19.1718 mL
5 mM 0.3834 mL 1.9172 mL 3.8344 mL
10 mM 0.1917 mL 0.9586 mL 1.9172 mL
  • 摩尔浓度计算器

  • 稀释计算器

  • 分子量计算器

质量
=
浓度
x
体积
x
分子量
 
 
 
*在配置溶液时,请务必参考产品标签上、MSDS / COA(可在Glpbio的产品页面获得)批次特异的分子量使用本工具。

计算

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % saline
计算重置

Research Update

Lysophospholipid G protein-coupled receptor binding parameters as determined by backscattering interferometry

J Lipid Res 2019 Jan;60(1):212-217.PMID:30463988DOI:PMC6314248

Lysophosphatidic acid (LPA) activates cognate G protein-coupled receptors (GPCRs) to initiate biological signaling cascades. Lysophospholipid (LP) receptor binding properties remain incompletely assessed because of difficulties with ligand lipophilicity and lipid "stickiness." These inherent attributes produce high levels of nonspecific binding within cell-membrane preparations used to assess GPCRs, as has been shown in classical binding assays using radiolabeled ligands, making accurate measurements of lipid binding kinetics difficult to achieve. Backscattering interferometry (BSI) is an optical technology that measures molecular binding interactions by reporting changes in the refractive index of a solution after binding events. Here, we report the use of BSI to assess LPA1 for its ability to bind to naturally occurring lipids and a synthetic LPA1 antagonist (ONO-9780307), under both primary- and competition-binding conditions. Assessment of 12 different lipids demonstrated that the known LP ligand, 1-oleoyl-LPA, as well as an endocannabinoid metabolite, anandamide phosphate, are specific ligands for LPA1, whereas other LPs tested were not. Newly determined dissociation constants (Kd values) for orthosteric lipid ligands approximated 10-9 M, substantially lower (i.e., with higher affinity) than measured Kd values in classical binding or cell-based assays. These results demonstrate that BSI may have particular utility in assessing binding interactions between lipid receptors and their lipid ligands and could provide new screening approaches for lipid receptor identification and drug discovery.